Document is current
Any future updates will be listed below
-
Authors
de Boer, Eva M. J. https://orcid.org/0000-0002-2629-2748
de Vries, Bálint S. https://orcid.org/0000-0001-9102-7353
Van Hecke, Wim
Mühlebner, Angelika
Vincken, Koen L.
Mol, Christian P.
van Rheenen, Wouter
Westeneng, Henk-Jan
Veldink, Jan H. https://orcid.org/0000-0001-5572-9657
Höglinger, Günter U. https://orcid.org/0000-0001-7587-6187
Morris, Huw R. https://orcid.org/0000-0002-5473-3774
Litvan, Irene https://orcid.org/0000-0002-3485-3445
Raaphorst, Joost
Ticozzi, Nicola
Corcia, Philippe https://orcid.org/0000-0002-1625-8845
Vandenberghe, Wim https://orcid.org/0000-0002-9758-5062
Pijnenburg, Yolande A. L.
Seelaar, Harro https://orcid.org/0000-0003-1989-7527
Ingre, Caroline https://orcid.org/0000-0001-5327-7204
Van Damme, Philip https://orcid.org/0000-0002-4010-2357
van den Berg, Leonard H. https://orcid.org/0000-0002-5203-9674
van de Warrenburg, Bart P. C. https://orcid.org/0000-0003-4412-1616
van Es, Michael A. https://orcid.org/0000-0002-7709-5883
- License Information
-
More Information
Article History
Received: 20 March 2024
Revised: 26 September 2024
Accepted: 28 September 2024
First Online: 12 December 2024
Declarations
:
: E.M.J. de Boer: reports no disclosures relevant to the manuscript. B.S. de Vries: reports no disclosures relevant to the manuscript. W. van Hecke: reports no disclosures relevant to the manuscript. A. Mühlebner: reports no disclosures relevant to the manuscript. K.L. Vincken: reports no disclosures relevant to the manuscript. C.P. Mol: reports no disclosures relevant to the manuscript. W. van Rheenen: reports no disclosures relevant to the manuscript. H-J Westeneng: reports no disclosures relevant to the manuscript. J.H. Veldink: reports to have sponsored research agreements with Biogen and Astra Zeneca. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement n° 772376 – EScORIAL. G.U. Höglinger: reports no disclosures relevant to the manuscript. H.R. Morris: reports no disclosures relevant to the manuscript. I. Litvan: reports no disclosures relevant to the manuscript. J. Raaphorst: reports no disclosures relevant to the manuscript. N. Ticozzi: reports no disclosures relevant to the manuscript. P. Corcia: reports no disclosures relevant to the manuscript. W. Vandenberghe: reports no disclosures relevant to the manuscript. Y.A.L. Pijnenburg: reports no disclosures relevant to the manuscript. H. Seelaar: reports no disclosures relevant to the manuscript. C. Ingre: reports no disclosures relevant to the manuscript. P. Van Damme: reports no disclosures relevant to the manuscript. L.H. van den Berg: declares fees to his institution from Biogen, Wave, Amylyx, Ferrer, and Cytokinetics for being on a scientific advisory board; fees to his institution from Amylyx for a lecture; an unrestricted educational grant from Takeda; and is the Chair of ENCALS and TRICALS. B.P.C. van de Warrenburg: reports no disclosures relevant to the manuscript. M.A. van Es: has consulted for Biogen, and has received travel grants from Shire (formerly Baxalta), performed work as a medical monitor for Ferrer (NCT05178810) with fees going to his institution. MAvE receives funding support from the Netherlands Organization for Health Research and Development (Vidi scheme), The Thierry Latran Foundation, the Motor Neurone Disease Association, FIGHT-MND and the ALS Foundation Netherlands. He is also a member of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD).
